Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Adults with Insomnia | 2 | GlobeNewswire (USA) | ||
05.12. | Nxera Pharma Enrolls First Insomnia Patient in its Phase 3 Clinical Trial of Daridorexant in South Korea | 79 | GlobeNewswire (Europe) | Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomniaQUVIVIQ (daridorexant) 25 and 50 mg was recently approved and is expected... ► Artikel lesen | |
13.11. | Nxera Pharma's Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist | 219 | GlobeNewswire (Europe) | Phase 2 trial initiation in patients with sleep /wake disorders results in milestone payment of US$3.5 million to Nxera Tokyo, Japan and Cambridge, UK, 13 November 2024 - Nxera Pharma Co., Ltd. ("Nxera"... ► Artikel lesen | |
06.11. | Nxera Pharma and Antiverse to design antibodies targeting GPCRs | 2 | Pharmaceutical Technology | ||
05.11. | Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI | 6 | GlobeNewswire (USA) | ||
01.11. | Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2024 | 142 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 1 November 2024 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) - formerly known as Sosei Group or Sosei Heptares - provides an update on operational... ► Artikel lesen | |
23.10. | Nxera Pharma Wins Biotech Company of the Year and Financing Deal of the Year at the Citeline Japan Awards 2024 | 12 | GlobeNewswire (USA) | ||
18.10. | Nxera Pharma to Host R&D Day 2024 | 1 | GlobeNewswire (USA) | ||
NXERA PHARMA Aktie jetzt für 0€ handeln | |||||
01.10. | Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ in Japan | 216 | GlobeNewswire (Europe) | QUVIVIQ is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomnia Tokyo, Japan and Cambridge, UK, 1 October 2024... ► Artikel lesen | |
01.10. | Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan | 122 | GlobeNewswire (Europe) | Dr. Sugita - formerly Vice President, Head of R&D for Bristol Myers Squibb in Japan - brings nearly 20 years' experience in R&D and commercial roles working within the Japanese businesses of global... ► Artikel lesen | |
24.09. | Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia | 328 | GlobeNewswire (Europe) | The approval of QUVIVIQ, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3 trial in Japan that met all primary and secondary endpointsPlans... ► Artikel lesen | |
13.09. | Nxera and Cancer Research UK to present promising cancer drug trial at ESMO | 2 | PharmaTimes | ||
13.09. | Nxera Pharma: Nxera's Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO | 2 | GlobeNewswire (USA) | ||
11.09. | Nxera Pharma's Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers | 220 | GlobeNewswire (Europe) | ORX750 showed clinically meaningful and statistically significant improvements in mean sleep latency and had a favorable safety and tolerability profile with no observations of frequently reported... ► Artikel lesen | |
02.09. | Nxera wins $35m after Phase II schizophrenia trial success | 1 | Pharmaceutical Technology | ||
02.09. | Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568 | 284 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 2 September 2024 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) - formerly known as Sosei Group or Sosei Heptares - announces that it will receive a... ► Artikel lesen | |
28.08. | Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568 | 421 | GlobeNewswire (Europe) | NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine BiosciencesThe once-daily... ► Artikel lesen | |
09.08. | Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2024 | 177 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 9 August 2024 - Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second... ► Artikel lesen | |
25.07. | TM and Singtel's Nxera break ground for sustainable, hyper-connected data centre campus in Johor | 2 | TechNode | ||
09.07. | Nxera Pharma Webinar Presentation for Q2 FY2024 Financial Results | 1 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 25,670 | -0,02 % | Prognose für 2025 präsentiert: Pfizer: So billig ist die 6,7-Prozent-Dividende jetzt zu haben! | © Foto: Foto: Nicolas Maeterlinck/ - BELGA/dpaDer US-Pharmakonzern hat am Dienstagmittag seine Prognose für das kommende Geschäftsjahr vorgestellt. Diese liegt größtenteils im Rahmen der Erwartungen.Pfizer... ► Artikel lesen | |
NOVARTIS | 93,78 | +0,53 % | DEUTSCHE BANK RESEARCH stuft NOVARTIS AG auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Novartis mit einem Kursziel von 100 Schweizer Franken auf "Hold" belassen. Dies schrieb der Analyst Emmanuel Papadakis in... ► Artikel lesen | |
GILEAD SCIENCES | 89,63 | -0,12 % | Assembly Bio: Gilead erhöht Anteil vor Readouts! | Während viele Biotech-Titel zum Jahresende noch einmal starke Kursabstürze erfahren, hält sich mein Top-Favorit Assembly Biosciences (WKN: A402CB) auf Jahressicht weiter stark mit einer Performance... ► Artikel lesen | |
SANOFI | 92,86 | -0,14 % | Sanofi SA-Aktie legt um 1,25 Prozent zu (88,88 €) | Im Plus liegt aktuell das Wertpapier von Sanofi SA . Der jüngste Kurs betrug 88,88 Euro. Heute hat sich am Aktienmarkt die Aktie von Sanofi SA zwischenzeitlich um 1,25 Prozent verteuert. Der Kurs des... ► Artikel lesen | |
ABBVIE | 171,00 | -0,24 % | PTA-News: Small- & MicroCap Investment: Mehr Potenzial als Eli Lilly oder AbbVie? Analysten mit Top-Prognosen für NurExone | DJ PTA-News: Small- & MicroCap Investment: Mehr Potenzial als Eli Lilly oder AbbVie? Analysten mit Top-Prognosen für NurExone
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt (pta/22.12.2024/10:30)... ► Artikel lesen | |
ROCHE | 267,90 | +1,17 % | Roche Aktie: Glückwünsche für ein starkes Quartal! | Die Schweizer Pharmagesellschaft Roche verzeichnet einen bedeutenden Fortschritt in ihrer Augenheilkunde-Sparte. Die Europäische Arzneimittelagentur hat kürzlich die Zulassung für eine gefüllte Spritze... ► Artikel lesen | |
ABBOTT LABORATORIES | 109,12 | -0,66 % | Abbott Completes In-human Left Bundle Branch Area Pacing Procedures Using AVEIR CSP Pacemaker | NORTH CHICAGO (dpa-AFX) - Abbott (ABT) announced the successful completion of the world's first in-human leadless left bundle branch area pacing procedures using the company's investigational... ► Artikel lesen | |
INCYTE | 66,96 | -0,27 % | Kaum Impulse für die Incyte-Aktie (66,9682 €) | Die Wertschätzung für das Wertpapier von Incyte hat sich am Aktienmarkt am Dienstag kaum geändert. Der jüngste Kurs betrug 69,60 US-Dollar. Kaum auffällig ist derzeit an der Börse der Kurs von Incyte.... ► Artikel lesen | |
EDWARDS LIFESCIENCES | 71,47 | -0,61 % | Edwards Lifesciences scores a win at CMS for TTVR | ||
WPD PHARMACEUTICALS | 0,002 | -33,33 % | CSE Bulletin: Consolidation - WPD Pharmaceuticals Inc. (WBIO) | le 23 décembre/December 2024
WPD Pharmaceuticals Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every twenty-five... ► Artikel lesen | |
HALEON | 4,632 | -0,24 % | Haleon plc - 6-K, Report of foreign issuer | ||
BIONANO GENOMICS | 0,201 | +0,95 % | Bionano Genomics: Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis | ||
TONIX PHARMACEUTICALS | 0,388 | -3,32 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia | Tonix received FDA's Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025 TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast... ► Artikel lesen | |
ALNYLAM PHARMACEUTICALS | 228,60 | -1,68 % | How Is The Market Feeling About Alnylam Pharmaceuticals? | ||
GRIFOLS | 9,358 | -1,35 % | Grifols SA - 6-K, Report of foreign issuer |